Chuck Royce's PVLA Position Overview
Chuck Royce (via Royce & Associates Lp) currently holds 30,010 shares of Palvella Therapeutics, Inc. (PVLA) worth $3.14 M, representing 0.03% of the portfolio. First purchased in 2025-Q1, this short-term holding has been held for 4 quarters.
Based on 13F filings, Chuck Royce has maintained this position in PVLA for several quarters, showing initial confidence in the investment. Largest addition occurred in Q2 2025, adding 3,002 shares. Largest reduction occurred in Q3 2025, reducing 25,007 shares.
Analysis based on 13F filings available since 2013 Q2
Chuck Royce's Palvella Therapeutics (PVLA) Holding Value Over Time
Track share changes against reported price movement
Quarterly Palvella Therapeutics (PVLA) Trades by Chuck Royce
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | -19,499 | Reduce 39.38% | 30,010 | $104.67 |
| Q3 2025 | -25,007 | Reduce 33.56% | 49,509 | $62.69 |
| Q2 2025 | +3,002 | Add 4.20% | 74,516 | $22.54 |
| Q1 2025 | +71,514 | New Buy | 71,514 | $27.99 |
Chuck Royce's Palvella Therapeutics Investment FAQs
Chuck Royce first purchased Palvella Therapeutics, Inc. (PVLA) in Q1 2025, acquiring 71,514 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Chuck Royce has held Palvella Therapeutics, Inc. (PVLA) for 4 quarters since Q1 2025.
Chuck Royce's largest addition to Palvella Therapeutics, Inc. (PVLA) was in Q1 2025, adding 71,514 shares worth $2 M.
According to the latest 13F filing for Q4 2025, Chuck Royce's firm, Royce & Associates Lp, owns 30,010 shares of Palvella Therapeutics, Inc. (PVLA), valued at approximately $3.14 M.
As of the Q4 2025 filing, Palvella Therapeutics, Inc. (PVLA) represents approximately 0.03% of Chuck Royce's publicly disclosed stock portfolio, making it one of their key holdings.
Chuck Royce's peak holding in Palvella Therapeutics, Inc. (PVLA) was 74,516 shares, as reported at the end of Q2 2025.